Edition:
United Kingdom

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

4,415JPY
22 Feb 2019
Change (% chg)

¥-25 (-0.56%)
Prev Close
¥4,440
Open
¥4,396
Day's High
¥4,435
Day's Low
¥4,373
Volume
5,918,400
Avg. Vol
10,408,892
52-wk High
¥6,221
52-wk Low
¥3,498

Select another date:

Tue, Feb 5 2019

Photo

U.S. jury orders Takeda to pay Bayer $155 million over hemophilia drug

A U.S. jury has ordered Takeda Pharmaceutical Co's Baxalta unit to pay Bayer AG $155.19 million for infringing a patent related to a Baxalta hemophilia treatment, court records made public on Tuesday show.

UPDATE 1-U.S. jury orders Takeda to pay Bayer $155 mln over hemophilia drug

Feb 5 A U.S. jury has ordered Takeda Pharmaceutical Co's Baxalta unit to pay Bayer AG $155.19 million for infringing a patent related to a Baxalta hemophilia treatment, court records made public on Tuesday show.

U.S. jury orders Takeda to pay Bayer $155 million over haemophilia drug

A U.S. jury has ordered Takeda Pharmaceutical Co's Baxalta unit to pay Bayer AG $155.19 million (£119.91 million) for infringing a patent related to a Baxalta haemophilia treatment, court records made public on Tuesday show.

U.S. jury orders Takeda to pay Bayer $155 mln over hemophilia drug

Feb 5 A U.S. jury has ordered Takeda Pharmaceutical Co's Baxalta unit to pay Bayer AG $155.19 million for infringing a patent related to a Baxalta hemophilia treatment, court records made public on Tuesday show.

Tokyo 2020 head says no need for Takeda to resign

TOKYO Japanese Olympic Committee President Tsunekazu Takeda, being probed for suspected corruption, does not need to step down from his role with the Tokyo 2020 organising committee because current "reports" do not justify action, the head of Tokyo 2020 said.

Olympics-Tokyo 2020 head says no need for Takeda to resign

TOKYO, Feb 1 Japanese Olympic Committee President Tsunekazu Takeda, being probed for suspected corruption, does not need to step down from his role with the Tokyo 2020 organising committee because current "reports" do not justify action, the head of Tokyo 2020 said.

Takeda's third-quarter profit rises 28 percent on strong sales of main drugs

TOKYO Takeda Pharmaceutical Co Ltd on Friday posted a 27.9 percent rise in third-quarter operating profit, supported by strong sales of its drugs for bowel disease and multiple myeloma.

Takeda's third-quarter profit rises 28 percent on strong sales of main drugs

TOKYO Takeda Pharmaceutical Co Ltd on Friday posted a 27.9 percent rise in third-quarter operating profit, supported by strong sales of its drugs for bowel disease and multiple myeloma.

UPDATE 1-Takeda's Q3 profit rises 28 pct on strong sales of main drugs

* Boosted by strong sales of bowel disease, multiple myeloma drugs (Adds sales details, divesting plans)

Japan's Takeda posts 28 pct rise in Q3 operating profit

TOKYO, Feb 1 Takeda Pharmaceutical Co Ltd on Friday posted a 27.9 percent rise in third-quarter operating profit, supported by strong sales of its drugs for bowel disease and multiple myeloma.

Select another date: